Insmed | INSM

Stock Price
19.54
Daily Change
1.56%
Yearly
0.05%
Q2 Forecast
18.25
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Alimera Sciences 2.68 0.07 2.68% -56.42%
BioMarin Pharmaceutical 93.36 5.10 5.78% 20.48%
Cytokinetics 38.63 0.67 1.77% -9.93%
DBV Technologies 1.99 0.03 1.53% 25.95%
Dynavax Technologies 11.66 0.18 1.57% -3.80%
Gilead Sciences 77.89 1.68 2.20% 22.76%
Heron Therapeutics 1.12 0.01 0.90% -62.67%
Insmed 19.54 0.30 1.56% 0.05%
Mirati Therapeutics 38.26 1.25 3.38% -13.69%
Novartis 98.91 1.80 1.85% 10.99%
Iveric bio Inc. 38.03 0.24 0.64% 253.44%
Ultragenyx Pharmaceutical 50.85 1.24 2.50% -1.09%
Regeneron Pharmaceuticals 739.95 8.78 1.20% 17.39%
Seattle Genetics 195.38 0.71 0.36% 39.62%
Sarepta Therapeutics 125.16 0.88 0.71% 71.50%
Vertex Pharmaceuticals 333.78 10.16 3.14% 23.88%

Indexes Price Day Year
USND 13241 139.78 1.07% 10.22%
US2000 1831 62.97 3.56% -2.77%

Insmed

Insmed traded at $19.54 this Friday June 2nd, increasing $0.30 or 1.56 percent since the previous trading session. Looking back, over the last four weeks, Insmed gained 1.31 percent. Over the last 12 months, its price rose by 0.05 percent. Looking ahead, we forecast Insmed to be priced at 18.25 by the end of this quarter and at 16.72 in one year, according to Trading Economics global macro models projections and analysts expectations.

Insmed Incorporated is a global biopharmaceutical company. The Company's product, ARIKAYCE (amikacin liposome inhalation suspension) is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which offers a differentiated product profile for pulmonary arterial hypertension (PAH) and other rare pulmonary disorders.